Shift of CTX-M genotypes has determined the increased prevalence of extended-spectrum β-lactamase-producing Escherichia coli in south-western Sweden  by Helldal, L. et al.
Shift of CTX-M genotypes has determined
the increased prevalence of extended-
spectrum b-lactamase-producing Escherichia
coli in south-western Sweden
L. Helldal1*, N. Karami1*, K. Floren1, C. Welinder-Olsson1,
E. R. B. Moore1,2 and C. A˚hren1,3
1) Department of Infectious Diseases, 2) Department of Infectious Diseases,
Culture Collection University of Gothenburg (CCUG) and 3) Infection
Control, Department of Infectious Diseases, Institute of Biomedicine,
Sahlgrenska Academy of the University of Gothenburg, Gothenburg, Sweden
Abstract
The prevalence of Escherichia coli producing extended-spectrum
b-lactamases (ESBLs) markedly increased during 2004–2008 in
south-western Sweden, with a greater increase in urinary isolates
in hospitals (0.2–2.5%) than in the community (0.2–1.6%). ESBLs of
genotype CTX-M predominated, with a signiﬁcant (p <0.02) shift
from the CTX-M-9 to CTX-M-1 phylogroup occurring among
urinary ESBL-producing E. coli isolated early (n = 41) as compared
with late (n = 221) in the study period. The increase in ESBL-
producing E. coli was polyclonal, and only partly attributable to an
increase (0–24%) in the number of O25b-ST131 isolates carrying
CTX-M-15. The increase was prominent in men and in elderly
patients, and warrants continued surveillance.
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The emerging pandemic of Enterobacteriaceae producing
extended-spectrum b-lactamases (ESBLs) poses a serious
threat to the successful treatment of common bacterial
infections. During the past decade, the CTX-M b-lactamases,
mainly associated with Escherichia coli, have emerged as the
predominant ESBL type worldwide [1]. CTX-M-15 and CTX-
M-14, belonging to the CTX-M-1 and CTX-M-9 phylogroups,
respectively, are currently the most widely distributed CTX-M
genotypes [2,3], and are increasingly associated with commu-
nity-acquired infections [1,4].
E. coli serotype O25b:H4 and sequence type (ST)131 by
multilocus sequence typing, carrying CTX-M-15, has been
reported worldwide [5,6]. Despite there being low levels of
multiresistant bacteria for decades, the frequency of ESBL-
producing bacteria has been reported to be increasing in the
Scandinavian countries [7–10].
We describe the epidemiology of ESBL-producing E. coli,
isolated from patients, in a municipal area in south-western
Sweden as the incidence of ESBLs began to increase. The
centralized microbiology laboratory services a 2000-bed
university hospital, a 200-bed tertiary hospital, 110 long-
term-care facilities, and 75 outpatient clinics, providing health
services to 750 000 inhabitants.
Bacterial isolation and identiﬁcation were performed with
conventional phenotypic analyses. Antibiotic susceptibilities
were conﬁrmed according to the Swedish Reference Group
for Antibiotics (http://www.nordicast.org) at the time. Ceph-
alosporin-resistant isolates were tested for ESBL phenotype,
by use of the double-disk diffusion test with clavulanic acid.
In agreement with recent reports, the majority of ESBL-
producing isolates were E. coli from urine samples of patients
in the community [1]. The prevalence of ESBL-producing E. coli
increased from 0.2% (23/11 337) to 1.9% (224/11 953) among
urine isolates during 2004–2008. The increase was greater in
the hospitals (to 2.5%; 82/3284) than in the community (to
1.6%; 142/8669). The corresponding numbers in blood samples
were 0–3% (13/434). Other Enterobacteriaceae producing
ESBLs were rare.
Non-repetitive ESBL-producing E. coli isolated from urine
samples during two periods (September 2003 to April 2005
and April 2008 to March 2009) were investigated further.
Respectively, 41 of 45 and 221 of 230 isolates could be
retrieved. Patient data were recorded from laboratory refer-
rals (Table 1). The distribution of ESBL-producing E. coli
reﬂected the distribution of urinary tract infections in the
general population. An increase in isolates carrying CTX-M
was seen in the elderly, constituting almost 50% of the isolates
in the later period. The number of isolates from men, which
were most prominent in men aged 18–65 years, increased
between the study periods, although not signiﬁcantly. These
increases could not be explained by the accumulation of a
single strain within a unit or time frame. Some transmission in
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hospitals and long-term-care facilities, although not causing
outbreaks, owing to lack of appropriate hygiene could, of
course, not be excluded. Higher usage of antibiotics in patient
cohorts known to select for resistant bacteria also has to be
taken into account, particularly in men with urinary tract
infections, who are often treated with quinolones.
The 262 isolates were analysed with an allele-speciﬁc
multiplex PCR for detection of O25b-ST131 strains [11], and
selected isolates (Table 2) were typed by pulsed-ﬁeld gel
electrophoresis (PFGE) genomic DNA proﬁling [12] and
multilocus sequence typing (http://mlst.ucc.i.e/dbs/Ecoli). The
isolates were analysed for CTX-M, TEM, OXA and SHV
TABLE 1. Distribution of CTX-M phylogroups and O25b-ST131 isolates in urinary Escherichia coli in relation to patient
categories during the two study periods
2003–2005 2008–2009
CTX-M-1 phylogroup CTX-M-9 phylogroup CTX-M-1 phylogroup CTX-M-9 phylogroup
Total no. O25b-ST131 Total no. O25b-ST131 Total no. O25b-ST131 Total no. O25b-ST131
Hospital 1 0 5 0 55 12 9 1
Female 1 – 3 – 29 6 9 1
<18 years 0 – 0 – 3 – 0 –
18–65 years 1 – 3 – 9 1 2 1
>65 years 0 – 0 – 17 5 7 –
Male 0 0 2 0 26 6 0 0
<18 years 0 – 0 – 3 – 0 –
18–65 years 0 – 0 – 8 1 0 –
>65 years 0 – 2 – 15 5 0 –
Community 19 4 11 0 111 35 37 4
Female 15 4 11 – 89 27 30 4
<18 years 1 – 1 – 5 – 2 –
18–65 years 9 4 7 – 52 17 15 4
>65 years 5 – 3 – 32 10 13 –
Male 4 – 0 – 22 8 7 –
<18 years 0 – 0 – 1 – 1 –
18–65 years 1 – 0 – 8 2 2 –
>65 years 3 – 0 – 13 6 4 –
Total 20 4 16 0 166 47 46 5
TABLE 2. Distribution of extended-spectrum b-lactamase (ESBL) genes, the O25b-ST131 genotype and the numbers of pulsed-











PFGE typesa Total No. of PFGE typesa Total
No. of
PFGE typesa
CTX-M-1 phylogroup 20b 16c 14/16 4c 3/4 166b 119c 46/53 47c 13/19
CTX-M-1 group only 1 1 – 0 – 23 21 – 2 –
CTX-M-1 group + TEM 4 4 – 0 – 51 45 – 6 –
CTX-M-1 group + OXA 11 7 – 4 – 58 29 – 29 –
CTX-M-1 group + TEM + OXA 4 4 – 0 – 34 24 – 10 –
CTX-M-9 phylogroup 16d 16e 12/13 0 – 46d 41f 13/15 5g 3/3
CTX-M-9 group only 7 7 – 0 – 10 6 – 4 –
CTX-M-9 group + TEM 9 9 – 0 – 35 34 – 1 –
CTX-M-9 group + TEM + OXA 0 0 – 0 – 1 1 – 0 –
Other ESBLs 5 5 – 0 – 9 7 – 2 –
CTX-M-2 group + TEM 0 0 – 0 – 3 2 – 1 –
CTX-M-1/9 group + TEM 0 0 – 0 – 1 1 – 0 –
SHV only 1 1 – 0 – 1 1 – 0 –
TEM only 2 2 – 0 – 0 0 – 0 –
OXA only 0 0 – 0 – 1 1 – 0 –
TEM + SHV 2 0 – 0 – 2 1 – 1 –
TEM + OXA 0 0 – 0 – 1 1 – 0 –
Total 41 37 26/29 4 3/4 221 167 59/68 54 16/22
aNo. of PFGE types/isolates tested, adding up to >80 PFGE types for the entire study period. These were distributed within at least 30 sequence types (STs) by MLST. ST131,
ST648, ST38, ST12, ST167, ST617, ST405 and ST69 were found in three or more isolates, listed in order of prevalence.
bThe proportion of CTX-M-1 phylogroup isolates among those with a CTX-M increased signiﬁcantly (p <0.002) between the two study periods.
cAll were CTX-M-15, i.e. the genes of all O25b-ST131 isolates, four of 16 non-O25b-ST131 isolates tested from the early period, and 11 of 119 tested from the late period. One
additional isolate from the last group harboured CTX-M-1.
dThe proportion of CTX-M-9 phylogroup isolates among those with CTX-M decreased signiﬁcantly (p <0.02) between the two study periods.
eOne isolate with CTX-M-9 and three with CTX-M-14. Genes from four isolates were sequenced.
fOne isolate with CTX-M-27 and the remainder with CTX-M-14. Genes from 11 isolates were sequenced.
gThree isolates with CTX-M-27 and two with CTX-M-14.
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genotypes, with a multiplex PCR assay [8], and subsequently
for CTX-M phylogroups, with a standardized PCR assay and a
Taq Man PCR protocol [13]. The CTX-M genes for selected
isolates were partially sequenced for conﬁrmation of genotype
(Table 2).
ESBL-producing E. coli O25b-ST131 clearly dominated
among the isolates, although its prevalence increased at a
later stage than reported elsewhere [3,6]. Its prevalence
increased signiﬁcantly (p <0.05) in the later period (26% in the
community, and 20% in the hospitals; Table 1). The low total
number, <0.5% of all urine E. coli isolates, may explain why the
increase, thus far, has been less dramatic and has not resulted
in increased community septicaemia rates, as has been
reported [14]. Isolates belonging to ST131 clearly dominated,
followed by ST648, ST38, and ST12, each of which was
detected in more than ﬁve isolates (Table 2). The isolates
represented >80 PFGE types, and fewer than four isolates per
type were found, with no accumulation in a unit, patient
cohort, or time frame.
The isolates carrying CTX-M dominated, representing 96%
of the genotypes in the later period, and the CTX-M types
found were in agreement with those reported in other
Scandinavian studies [7–10]. In hospitals, the CTX-M-9 phylo-
group dominated in the early period, but there was a shift
towards the distribution in the community, with a predomi-
nance of the CTX-M-1 phylogroup. Overall, this shift in favour
of the CTX-M-1 phylogroup was signiﬁcant (p <0.02). Similar
shifts have been reported in Canada and Spain [15,16]. The
predominance of the strain type O25b-ST131 with CTX-M-15
did not explain the overall migration of CTX-M genotypes, and
nor did an accumulation or shift of particular strain types.
In the later period, multiresistance to tobramycin, cipro-
ﬂoxacin and trimethoprim increased, and was found more
often together with the CTX-M-1 phylogroup than with the
CTX-M-9 phylogroup (p <0.004, 77/166 vs. 10/46). The O25b-
ST131 isolates displayed such multiresistance more often than
non-O25b-ST131 isolates harbouring genes of the CTX-M-1
phylogroup (p <0.05, 28/47 vs. 49/119).
The varying resistance phenotypes, b-lactamase combina-
tions, STs and PFGE types and the absence of accumulation
suggested that the increase was polyclonal. We cannot exclude
the possibility that it was partly a result of importation through
foreign travel, as ESBL-producing E. coli isolates with similar
enzyme proﬁles have been reported in returning Swedish
travellers [17].
In conclusion, this study demonstrates that Sweden is
affected by the global ESBL pandemic. Isolates with the CTX-
M-1 phylogroup enzymes are well established, particularly the
O25b-ST131 isolates carrying CTX-M-15, and are entering the
hospitals from the community. In contrast to previous
epidemics of multiresistant bacteria, and despite low antibiotic
pressure and low resistance levels in Sweden in general
[18,19], we face an impact from the worldwide epidemic
similar to what is seen in other countries. This could be
attributable to the polyclonal nature of emerging strains and
their establishment within the community. The increase among
the elderly and in men, and the concomitant increase in
antibiotic resistance, are of great concern, and warrant
continued surveillance of the ESBL pandemic also at the local
level.
Statistics
p-Values were calculated with Fisher’s exact test.
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